Peter M. Fischer

Overview

Best Publications

• The Chemistry of Redox-Flow Batteries.

  Jens Noack;Nataliya Roznyatovskaya;Tatjana Herr;Peter Fischer

  663
  Citations

• Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

  Julie A. Moreno;Mark Halliday;Colin Molloy;Helois Radford

  608
  Citations

• Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

  Michael P. Mazanetz;Peter M. Fischer

  607
  Citations

• In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).

  Steven J. McClue;David Blake;Rosemary Clarke;Angela Cowan

  474
  Citations

• Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.

  M Halliday;H Radford;Y Sekine;J Moreno

  331
  Citations

• Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

  Shudong Wang;Peter M. Fischer

  295
  Citations

• Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

  Peter M. Fischer;David P. Lane

  275
  Citations

• Diketopiperazines in peptide and combinatorial chemistry

  Peter M. Fischer

  260
  Citations

• Mutations in a translation initiation factor identify the target of a memory-enhancing compound

  Yusuke Sekine;Alisa Zyryanova;Ana Crespillo-Casado;Peter M. Fischer

  224
  Citations

• Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin.

  Peter M. Fischer;N. Z. Zhelev;S. Wang;J. E. Melville

  221
  Citations

• 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects†

  Vladimir Krystof;Petr Cankar;Iveta Frysova;Jan Slouka

  219
  Citations

• 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

  Shudong Wang;Christopher Meades;Gavin Wood;Andrew Osnowski

  201
  Citations

• Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation.

  Peter M. Fischer;Eberhard Krausz;David P. Lane

  197
  Citations

• Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.

  Stanislava Uhrinova;Dusan Uhrin;Helen Powers;Kathryn Watt

  193
  Citations

• CDK inhibitors in clinical development for the treatment of cancer

  Peter M Fischer;Athos Gianella-Borradori

  187
  Citations

• Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B

  Alisa F. Zyryanova;Félix Weis;Alexandre Faille;Akeel Abo Alard

  183
  Citations

• Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

  Peter M Fischer;Athos Gianella-Borradori

  182
  Citations

• The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review

  Fischer Pm

  178
  Citations

• In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

  Florence I Raynaud;Steven R Whittaker;Peter M Fischer;Steven McClue

  165
  Citations

• The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases

  P. M. Fischer

  161
  Citations